

The role of inflammation in the association between overall and visceral adiposity and subclinical atherosclerosis

T. Christen ^{a,*}, S. Trompet ^b, P.C.N. Rensen ^{c,d}, K. Willems van Dijk ^{c,d,e}, H.J. Lamb ^f, J.W. Jukema ^g, F.R. Rosendaal ^a, S. le Cessie ^{a,h}, R. de Mutsert ^a

^a Department of Clinical Epidemiology, Leiden University Medical Center (LUMC), PO Box 9600, 2300, RC, Leiden, the Netherlands

^b Department of Medicine, Division of Gerontology and Geriatrics, LUMC, PO Box 9600, 2300, RC, Leiden, the Netherlands

^c Department of Medicine, Division of Endocrinology, LUMC, PO Box 9600, 2300, RC, Leiden, the Netherlands

^d Einthoven Laboratory for Experimental Vascular Medicine, LUMC, PO Box 9600, 2300, RC, Leiden, the Netherlands

^e Department of Human Genetics, LUMC, PO Box 9600, 2300, RC, Leiden, the Netherlands

^f Department of Radiology, LUMC, PO Box 9600, 2300, RC, Leiden, the Netherlands

^g Department of Cardiology, LUMC, PO Box 9600, 2300, RC, Leiden, the Netherlands

^h Department of Biomedical Data Sciences, LUMC, PO Box 9600, 2300, RC, Leiden, the Netherlands

Received 15 October 2018; received in revised form 23 February 2019; accepted 17 March 2019

Handling Editor: A. Siani

Available online 28 March 2019

KEYWORDS

Obesity;
Inflammation;
Mediation;
C-reactive protein;
Atherosclerosis

Abstract *Background and aims:* Inflammation may underlie the association between obesity, atherosclerosis and cardiovascular disease. We investigated to what extent markers of inflammation mediate associations between overall and visceral body fat and subclinical atherosclerosis. *Methods and results:* In this cross-sectional analysis of the Netherlands Epidemiology of Obesity study we estimated total body fat (TBF) by bio-impedance analysis, carotid artery intima media thickness (cIMT) by ultrasound, C-reactive protein (hs-CRP) and glycoprotein acetyls (GlycA) concentrations in fasting blood samples ($n = 5627$), and visceral adipose tissue (VAT) by magnetic resonance imaging ($n = 2247$). We examined associations between TBF and VAT, and cIMT using linear regression, adjusted for potential confounding factors, and for mediators: cardiometabolic risk factors (blood pressure, glucose and low-density lipoprotein cholesterol), and inflammation using CRP and GlycA as proxies.

Mean (SD) cIMT was 615 (90) μm . Per SD of TBF (8%), cIMT was 19 μm larger (95% confidence interval, CI: 10, 28). This association was 17 μm (95% CI: 8, 27) after adjustment for cardiometabolic risk factors, and did not change after adjustment for markers of inflammation. Per SD (56 cm^2) VAT, cIMT was 9 μm larger (95% CI: 2, 16) which changed to 5 μm (95% CI: -3, 12) after adjustment for cardiometabolic risk factors, and did not change after adjustment for inflammatory markers.

Conclusion: Our results suggest that associations between measures of overall and visceral body fat and subclinical atherosclerosis are not mediated by inflammation as measured by CRP and GlycA. Obesity may exert cardiovascular risk via other markers of systemic inflammation.

© 2019 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.

Introduction

Obesity, and in particular abdominal adiposity, is a well-established cause of coronary heart disease, stroke, and

* Corresponding author. C7-P, PO Box 9600, 2300, RC, Leiden, the Netherlands.

E-mail address: t.christen@lumc.nl (T. Christen).

atherosclerosis [1,2]. Between 40 and 50% of the association between obesity and cardiovascular diseases is mediated by three major cardiometabolic risk factors blood pressure, low-density lipoprotein cholesterol (LDL-c) and fasting glucose concentrations [3]. A low-grade systemic state of inflammation may partly mediate the relation between measures of body fat and cardiovascular disease [4] (Fig. 1).

Body fat, and in particular visceral fat, is infiltrated by pro-inflammatory (M1)-type macrophages, which contribute to a low-grade systemic inflammatory state by producing and secreting pro-inflammatory cytokines like IL-6, TGF-β, which is considered to have a detrimental effect on atherosclerosis [5–7]. C-reactive protein (CRP) and glycoprotein acetyls (GlycA) may also be used as biomarkers of low-grade systemic inflammation [8]. CRP is produced by the liver upon stimulation by inflammatory cytokines, while GlycA is a composite marker of glycosylated acute phase protein concentrations [9]. Both markers

Table 1 Baseline characteristics of participants of the NEO study aged between 45 and 65 years, without history of cardiovascular disease. (n = 5627).

	Total population	Men (43%)	Women (57%)
Age (years)	56 (6)	56 (6)	55 (6)
BMI (kg/m ²)	26 (4)	27 (3)	25 (4)
Total body fat (%)	31 (8)	25 (5)	36 (7)
Visceral adipose tissue (cm ²) (n = 2247)	90 (56)	115 (58)	67 (43)
Current smoking (%)	16	18	14
Alcohol intake (g/day)	10 (3–21)	16 (6–28)	8 (2–15)
Physical activity (MET h/week)	30 (16–50)	31 (15–51)	29 (16–49)
Education level (% high)	47	49	45
Diabetes (%)	5	7	3
Statin use (%)	8	11	6
Systolic blood pressure (mmHg)	131 (17)	135 (15)	127 (18)
Diastolic blood pressure (mmHg)	83 (10)	85 (10)	82 (10)
Triglycerides (mmol/L)	1.2 (0.8–1.7)	0.9 (0.7–1.3)	0.9 (0.7–1.3)
LDL cholesterol (mmol/L)	3.6 (0.9)	3.6 (1.0)	3.6 (1.0)
Glucose (mmol/L)	5.6 (1.2)	5.3 (0.8)	5.3 (0.7)
hs-CRP (mg/L)	1.1 (0.6–2.1)	1.2 (0.6–2.5)	1.1 (0.6–2.3)
Glycoprotein acetyls (mmol/L)	1.2 (1.1–1.3)	1.2 (1.1–1.3)	1.2 (1.1–1.3)
Carotid intima media thickness (μm)	615 (90)	625 (93)	605 (86)

Values are represented as mean (SD), median (25th–75th percentile) or percentage. Results were based on analyses weighted towards the BMI distribution of the general population (n = 5627). hs-CRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; MET, metabolic equivalent; NEO, Netherlands Epidemiology of Obesity; SAT, abdominal adipose tissue; TBF, total body fat mass; SD, standard deviation; VAT, visceral adipose tissue.

Table 2 Linear regression coefficients of the associations between measures of body fat and markers of inflammation, adjusted for potential confounding factors (total body fat: n = 5627; VAT: n = 2247).

		Regression coefficients between SDs of measures of body fat and markers of inflammation	
		hs-CRP (%)	GlycA (%)
Total body fat (SD: 8%)	Crude	40 (35, 44)	3 (3,4)
	Adjusted	71 (63, 79)	9 (8,9)
VAT (SD: 56 cm ²)	Crude	42 (35, 50)	9 (8,10)
	Adjusted	33 (24, 42)	6 (5,7)

Values represent relative change (%) in markers of inflammation per standard deviation of measures of body fat. Results were based on analyses weighted towards the BMI distribution of the general population (n = 5627; 2247 for VAT), and adjusted for potential confounding factors: age, sex, tobacco smoking, ethnicity, education and physical activity. Analyses with VAT were additionally adjusted for total body fat.

GlycA, glycoprotein acetyls; hs-CRP, high-sensitivity C-reactive protein; SD, standard deviation; VAT, visceral adipose tissue.

are observationally associated with arterial stiffness and cardiovascular disease and can therefore be used as a proxy for low-grade systemic inflammation [10–14]. Previous studies suggested a role for inflammation in cardiovascular outcomes, such as myocardial infarction and stroke [15–18]. A secondary analysis of the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) indicated that reduction of the risk of cardiovascular disease following canakinumab treatment was related with the reduction in CRP concentration [19]. However, the potential mediating role of a low-grade systemic inflammatory state between obesity and subclinical atherosclerosis has not been quantified.

We aimed to investigate the role of low-grade systemic inflammation, in addition to the main known cardiometabolic risk factors, in the associations between overall and visceral body fat with subclinical atherosclerosis.

Table 3 Linear regression coefficients of the associations between markers of inflammation and intima media thickness, adjusted for potential confounding factors (n = 5627).

Regression coefficients between SD of markers of inflammation and cIMT (μm)	Model	
	Crude	Multivariate
hs-CRP	11 (5,17)	1 (–4, 7)
GlycA	15 (9,20)	2 (–2, 5)

Values represent difference in cIMT per standard deviation of markers of inflammation. Results were based on analyses weighted towards the BMI distribution of the general population (n = 5627), and adjusted for potential confounding factors: age, sex, tobacco smoking, ethnicity, education and physical activity, blood pressure, LDL-cholesterol, fasting glucose, and total body fat.

BMI, body mass index; cIMT, carotid intima media thickness; GlycA, glycoprotein acetyls; hs-CRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; SD, standard deviation.

Table 4 Linear regression coefficients of the associations between measures of body fat and intima media thickness, adjusted for potential confounding factors (total association), hs-CRP and GlycA (direct association), and known cardiometabolic risk factors (systolic blood pressure, LDL-c, and glucose) (TBF: $n = 5627$; VAT: $n = 2247$).

	Regression coefficients between SD of measures of body fat and IMT (μm):	
	Total body fat (SD: 8%)	VAT (SD: 56 cm^2)
Model 1 (crude)	6 (2,9)	24 (19,29)
Model 1 + age and sex	26 (22,30)	19 (13,24)
Model 2 (adjusted)	19 (10,28)	9 (2,16)
Model 3A (Model 2 + cardiometabolic risk factors)	17 (8,27)	5 (-3, 12)
Model 3B (Model 2 + hs-CRP)	17 (8,27)	7 (-0, 15)
Model 3C (Model 2 + GlycA)	17 (8,26)	6 (-1, 14)
Model 3D (Model 2 + hs-CRP + GlycA)	16 (7,26)	6 (-2, 13)
Model 4 (Model 2 + cardiometabolic risk factors + hs-CRP + GlycA)	16 (6,25)	3 (-5, 11)

Results were based on analyses of the associations between measures of body fat and intima media thickness in participants of the Netherlands Epidemiology of Obesity study, weighted towards the BMI distribution of the general population ($n = 5627$; 2247 for VAT). The adjusted analyses in Model 2 and further were adjusted for potential confounding factors: age, sex, tobacco smoking, ethnicity, education and physical activity. Model 3B-3D were additionally adjusted for hs-CRP, GlycA, and both. Model 4 was additionally adjusted for cardiometabolic mediating risk factors: systolic blood pressure, LDL-c and fasting glucose.

Abbreviations: GlycA, glycoprotein acetyls; hs-CRP, high-sensitivity C-reactive protein; LDL-c, low-density lipoprotein cholesterol; SD, standard deviation; VAT, visceral adipose tissue.

Methods

Study population

The present study is a cross-sectional analysis of baseline measurements of the Netherlands Epidemiology of Obesity (NEO) study, a population-based, prospective cohort study ($n = 6671$). The study design and population are described in detail elsewhere [20].

Men and women aged 45–65 years with a BMI ≥ 27 kg/m^2 were eligible to participate in the NEO study. In addition, inhabitants of Leiderdorp were invited irrespective of their BMI to serve as a reference group with a BMI distribution of the general population. Prior to the baseline study visit, participants completed questionnaires at home with respect to demographic, lifestyle, and clinical information. Research nurses recorded names and dosages of current medication.

The design of the NEO study was approved by the Medical Ethical Committee of the Leiden University Medical Center (LUMC). All participants gave their written informed consent.

Data collection

Because more than 95% of participants in the NEO study were white, self-reported ethnicity was regrouped into white and other. The highest completed level of education was reported in ten categories and regrouped into two categories: low education (no education, primary education or lower vocational education) and high education (other). Smoking was reported in three groups: never, former, and current smoker. The SQUASH questionnaire was used to self-report physical activity during leisure time in hours per week of metabolic equivalents of task [21]. Participants self-reported their medical history of diabetes and cardiovascular disease (defined as myocardial infarction, angina, congestive heart failure, stroke or peripheral vascular disease). Height was measured without shoes using a calibrated, vertically fixed tape measure. Blood pressure was measured seated on the right arm with a validated automatic oscillometric device (OMRON, Model M10-IT; Omron Health Care Inc, IL, USA). The mean of three measurements was used to calculate the mean systolic and diastolic blood pressure levels.

Measures of overall and visceral adiposity

Body weight and total body fat percentage (TBF) were assessed in the morning after the ingestion of a standard liquid mixed meal (400 mL) after >10 h of fasting, using a bio-impedance device (TBF-310, Tanita International Division, UK). BMI was calculated by dividing body weight in kilograms by body height in meters squared. Abdominal visceral adipose tissue (VAT) was assessed by magnetic resonance imaging (MRI, 1.5 T MR imaging, Philips Medical Systems, Best, the Netherlands) using a turbo spin echo imaging protocol in a random subgroup of 2580 individuals without contraindications for MRI (implanted metallic devices, a body circumference >1.70 m, or claustrophobia). At the level of the fifth lumbar vertebra, three 10 mm transverse images were obtained during a breath-hold, using the following imaging parameters: TR = 300 ms; TE = 20 ms; flip angle = 90° ; slice thickness = 10 mm, slice gap = 2 mm [22]. The visceral fat areas was determined manually by a radiologist in training, and the quantified by converting the number of pixels to cm^2 for all three slices, of which the average was used in the analyses, using in-house-developed software (MASS, Medis, Leiden, the Netherlands).

Carotid intima media thickness

To obtain cIMT, ultrasonography of the common carotid arteries (CCA) was performed. A 15 mm long section 10 mm proximal of the CCA bifurcation was measured while the subject was in supine position. IMT was measured using a 7.5–10 MHz linear-array probe and the Art.Lab system (ART.LAB version 2.1, Esaote, Maastricht, The Netherlands) in B-mode setting and using a wall-track system to detect boundaries between lumen and intima, and between media and adventitia. cIMT was reported as




Figure 1 Directed acyclic graph of the hypothesized relations between measures of body fat and (subclinical) atherosclerosis, the total association (A) may be separated in a direct association (B), and an indirect association (C) via inflammation. LDL-c, low density lipoprotein cholesterol.

the mean of three measurements in angles of 180, 135 and 90° (right CCA) and 180, 225 and 270° (left CCA). A validation study was performed in 183 randomly selected participants, in whom all measurements were repeated. The intra-observer coefficient of variation of the intima media thickness measurements was 5.8%, and the inter-observer coefficient of variation was 9.0% [23].

Blood measurements

Plasma glucose, serum triglyceride, serum high-density lipoprotein-cholesterol (HDL-c), and serum total cholesterol concentrations were determined in fasting blood samples at the central clinical chemistry laboratory of the LUMC using standard assays. LDL-c concentrations were calculated using the Friedewald equation. The homeostatic model assessment of insulin resistance (HOMA-IR) was calculated by dividing the product of fasting glucose and fasting insulin by 22.5 [24].

Serum concentrations of CRP were determined in a fasting blood sample using a high sensitivity CRP assay (hs-CRP, TINA-Quant CRP HS system, Roche, Germany and

Modular P800, Roche, Germany). GlycA concentrations were measured in plasma that had undergone one previous freeze-thaw cycle, using a high-throughput proton nuclear magnetic resonance (NMR) spectroscopy (Nightingale Health Ltd., Helsinki, Finland) [25]. We calculated intraclass coefficients for 94 participants with repeated CRP and GlycA measurements during a second visit within 3–5 months of the first visit. For CRP, the intraclass coefficient was 0.31, and for GlycA 0.64.

Statistical analysis

For the present analysis, we excluded participants with a medical history of cardiovascular disease, participants with hs-CRP concentrations ≥ 10 mg/L, or using medication that targets systemic inflammation (corticosteroids, lumiracoxib or naproxen [26,27]), and participants with missing data.

Participants with a BMI ≥ 27 kg/m² were oversampled in the NEO study. To correct for the bias that would result from this oversampling, analyses were inverse probability weighted towards the BMI distribution of the NEO

participants from Leiderdorp, whose BMI distribution was similar to the general Dutch population [28,29]. All results were based on weighted analyses. Consequently, the results apply to a population-based study without oversampling of individuals with a BMI ≥ 27 kg/m².

Baseline characteristics were calculated for the total population, and for men and women separately, and expressed as mean (standard deviation, SD), median (25th-75th percentile) or percentage. To be able to compare the strength of the associations between the analyses with different measures of adiposity, the measures of adiposity were standardized to a mean of zero and standard deviation of one. Hs-CRP and GlycA concentrations were skewed, and therefore log-transformed to the natural logarithm. To examine multicollinearity for hs-CRP and GlycA, variance inflation factors (VIF) were calculated, which were all under 10 and therefore considered acceptable.

Mediation analyses

To examine the role of inflammation in the associations between visceral and total body fat and atherosclerosis, we performed mediation analysis according to Baron and Kenny and evaluated the assumptions [30].

First, we estimated the total association between measures of body fat and intima media thickness with linear regression analyses, and adjusted crude analyses for potential confounding factors age, sex, tobacco smoking, physical activity, statin use, ethnicity, education, and the other measure of body fat and calculated regression coefficients with 95% confidence intervals.

Second, we examined the assumptions for the Baron and Kenny method of mediation analyses. One of the assumptions is the absence of interaction between the exposure and the mediator. To examine this assumption, we included a multiplicative interaction term of the measures of body fat with the markers of inflammation in the linear regression model of the total association. We assessed linearity by plotting residuals, kernel density, P-P, and Q-normal distributions.

Furthermore we estimated the associations between the measures of body fat and the measures of inflammation by linear regression analysis, crude and adjusted for confounding factors. Because the measures of inflammation were log-transformed, we antilog-transformed the regression coefficients. As a result, the reported regression coefficients and 95% confidence intervals can be interpreted as a relative change in inflammatory marker per standard deviation of body fat.

We estimated the associations between the measures of inflammation and intima media thickness using linear regression analysis. We reported the regression coefficients and 95% confidence intervals, which can be interpreted as the difference in intima media thickness per standard deviation of the measures of inflammation.

Subsequently, we assessed mediation of the total association between measures of body fat and intima media thickness by known cardiometabolic risk factors for

cardiovascular disease: systolic blood pressure, LDL-c, and fasting glucose concentrations, and by the markers of inflammation separately and simultaneously. Therefore we additionally adjusted the regression models that were already adjusted for potential confounding factors for the cardiometabolic risk factors and markers of inflammation. We reported regression coefficients with 95% confidence intervals, which can be interpreted as the part of the association between measures of body fat and cIMT that does not go through the known cardiometabolic risk factors and measures of inflammation [30]. This association is often referred to as the direct effect [30].

We used TBF as measure of total body fat, as this measure is widely used and easy to interpret. The use of bioimpedance to assess TBF may have introduced imprecision. Therefore we repeated the analyses using abdominal subcutaneous adipose tissue, measured by MRI, as a sensitivity analysis. The use of fasting glucose may have introduced measurement error as a marker of insulin resistance. Therefore we performed additional sensitivity analyses, adding HOMA-IR to mediation models with the cardiometabolic risk factors. To assess the robustness of the models, we repeated all analyses including previously excluded participants with a history of CVD. Initial exclusion of participants with hs-CRP concentrations ≥ 10 mg/L, may introduce selection bias [31]. Therefore, we performed sensitivity analyses including these participants. Furthermore, mediation analysis with a mediator that is measured with error may lead to strongly biased results [31]. Therefore, we performed a sensitivity analysis with an assumed random measurement error of 35% using the *eivreg* command in STATA (Statacorp, College Station, Texas, USA), version 14.0.

Results

Participants that used medication with effects on markers of inflammation ($n = 137$) or had missing data ($n = 231$), with a history of cardiovascular disease ($n = 437$), or with hs-CRP concentrations ≥ 10 mg/L ($n = 267$) were excluded. In total, 5627 participants with a mean age of 56 years (SD: 6), mean BMI was 26 kg/m² (SD: 4) and of whom 43% men were included in the analysis. Of these, 2247 underwent MRI and had assessment of VAT (Table 1).

Assessing the associations between exposure, mediators and outcome

We first examined associations between the measures of body fat and markers of inflammation. Adjusted linear regression coefficients showed that per standard deviation of total body fat (8%) and visceral fat (56 cm²), hs-CRP concentrations were 71% (95% CI: 63, 79) and 33% (95% CI: 24, 42) higher. Per standard deviation of total body fat and visceral fat, GlycA concentrations were 9% (95% CI: 8, 9) and 6% (95% CI: 5, 7) higher (Table 2). Measures of body fat were also associated with the cardiometabolic risk factors glucose, LDL-c, and blood pressure (data not shown). As for the association between the markers of

inflammation and cIMT, the difference in cIMT was 1 μm (95% CI: -4, 7) per standard deviation of hs-CRP, and 2 μm (95% CI: -2, 5) per standard deviation of GlycA (Table 3).

No interaction was observed when multiplicative interaction terms between body fat and measures of inflammation were added in linear regression analyses between measures of body fat and intima media thickness.

Mediation analyses

The analyses for the total association between body fat and intima media thickness showed that one standard deviation of total body fat was associated in the crude model with a 6 μm (95% CI: 2, 9) larger intima media thickness, which changed to 19 μm (95% CI: 10, 28) after adjustment for potential confounding factors. One SD of VAT was associated in the crude model with 24 μm (95% CI: 19, 29) larger cIMT, which changed to 9 μm (95% CI: 2, 16) per SD in the adjusted model.

The association between one SD of total body fat and intima media thickness decreased from 19 to 17 μm (95% CI: 8, 27) after adjustment for systolic blood pressure, LDL-c, and fasting glucose concentrations and to 16 μm (95% CI: 6, 25) after additional adjustment for hs-CRP and GlycA. The association between visceral fat and intima media thickness decreased from 9 to 5 μm (95% CI: -3, 12), and to 3 μm (95% CI: -5, 11) after additional adjustment for hs-CRP and GlycA (Table 4).

Sensitivity analyses

The observed associations were similar when using abdominal subcutaneous adipose tissue, measured by MRI or adding HOMA-IR as a mediator (results not shown). The observed associations did not change substantially when including participants with a history of cardiovascular disease or diabetes or with hs-CRP concentrations in excess of 10 mg/L (data not shown). Furthermore, the observed associations did not change after adjustment for measurement error in the mediators (Supplementary Table 1).

Discussion

In this population-based study, we confirmed that in particular total body fat and to a lesser extent visceral fat were strongly associated with markers of inflammation, and modestly associated with cIMT. However, we observed no association between markers of inflammation and cIMT, which violated one of the main assumptions of a mediation analysis: the presence of an association between mediator and outcome. Consequently, we did not observe mediation of the association between measures of body fat and cIMT by markers of inflammation.

After adjustment for potential confounding factors, of which adjustment for sex had the strongest effect, we observed stronger association with markers of inflammation for total body fat than visceral fat. This was discordant with previous literature that found stronger associations

for visceral fat [32]. A potential explanation is that we used an accurate measure of visceral fat using MRI, and adjusted the associations for total body fat. Although visceral fat secretes cytokines at a higher rate than subcutaneous fat, visceral fat has a limited volume, and therefore contributes less to total inflammatory marker concentrations [33].

The role of inflammation in the development of atherosclerosis and cardiovascular disease has been debated for several years. While atherosclerosis is an inflammatory disease [34], CRP has been shown to be non-causal in the development of atherosclerosis and cardiovascular disease [18]. GlycA is a biological proxy of inflammation, as it is a measure of N-linked acute-phase proteins, which are secreted by the liver in response to stimulation by IL-6 [35]. Higher GlycA concentrations also predict an increased risk of CVD, independent of CRP [10]. Previous studies suggested that up to eight percent of the association between obesity and cardiovascular disease is mediated by inflammation [3,4]. However, we did not observe an association between markers of inflammation and subclinical atherosclerosis, which precluded mediation.

This inconsistency between our and previous studies may be attributed to a difference in populations and markers of (subclinical) cardiovascular disease that were studied. Previous studies were performed in individuals at high cardiovascular risk, while we were specifically interested in the associations in individuals from the general population that are not (yet) at high risk for cardiovascular disease. The main clinical trial that investigated the effects of inhibition of inflammation with the strong anti-inflammatory drug canakinumab on cardiovascular disease incidence was also performed in patients at very high cardiovascular risk, and found only a small cardiovascular risk reduction but no net effect on all-cause mortality [16]. This may suggest that inflammation plays an important role in a later stage of atherosclerosis or the transition towards coronary events. In addition, this may explain that we observed a limited magnitude of mediation by the cardiometabolic risk factors LDL-cholesterol, blood pressure and glucose. Second, atherosclerosis is considered an inflammatory disease [7]. Therefore it is possible that the inflammation of interest originates from atherosclerotic lesions, which may not be reflected by serum concentrations of hs-CRP and GlycA given the short half-lives of most cytokines.

Strengths of this study are that the analyses were performed in a large and well phenotyped population in which an objective measure of subclinical atherosclerosis and relevant measures of overall and visceral adiposity were available. Two separate inflammation markers have been analysed with similar results. The possibility of measurement error was taken into account and our results showed that this error had very limited potential implications for our conclusions.

This study also has some limitations. First, cIMT measures subclinical atherosclerosis with a degree of uncertainty. However, our measurement of cIMT had a

fair replicability [23]. Second, hs-CRP and GlycA are merely non-specific markers of low-grade systemic inflammation. Therefore, these concentrations may measure the true degree of systemic inflammation with error. This measurement error may severely bias the results of a mediation analysis [31]. However, as the markers of inflammation were robustly associated with total body fat and visceral fat, it is likely that concentrations of these markers truly reflected low-grade chronic inflammation associated with adipose tissue. Future studies could investigate more clinical measures of inflammation, such as leukocyte or monocyte counts. Also, the results did not essentially change upon correction for measurement error in all mediators. In addition, the use of bio-impedance may have introduced imprecision in the measurement of total body fat, compared to e.g. MRI or dual energy X-ray absorptiometry. This may have introduced bias towards the null into the results of this study. However, the results of sensitivity analyses using abdominal subcutaneous adipose tissue as measured by MRI were similar. Insulin resistance may be better measured by HOMA-IR than by fasting glucose, which has been used in previous mediation studies [3,4]. However, adding HOMA-IR as a potential mediator in sensitivity analyses did not change the results. The role of the cardiometabolic risk factors, and insulin resistance in early atherosclerosis may be investigated in further studies. Furthermore, exclusion of participants with a history of cardiovascular disease to prevent reverse causation may have restricted our study population to individuals without clinically relevant atherosclerosis. However, our results did not change upon including these participants in sensitivity analyses. Finally, due to the observational nature of this study, unmeasured confounding or reverse causation may be present, that could specifically influence mediation analysis [36].

In conclusion, in this population-based study we observed no association between two markers of sub-clinical inflammation and cIMT, and no mediation by these markers of inflammation of the association between measures of body fat and intima media thickness. Further research may reveal other mediators of the relation between overweight and obesity and atherosclerosis.

Conflicts of interest

The authors declare that they have no conflict of interest.

Author contributions

JWJ, FRR, RdM designed the study, PCNR, KWvD, and HJL collected data ST, RdM conceived the outline of the protocol, TC performed the analyses SIC verified the methodological approach, TC drafted the manuscript, all authors critically revised and contributed to the final manuscript.

Acknowledgements

We express our gratitude to all individuals who participate in the Netherlands Epidemiology in Obesity study. We are grateful to all participating general practitioners for inviting eligible participants. We furthermore thank P R van Beelen and all research nurses for collecting the data and P J Noordijk and her team for sample handling and storage and I de Jonge, MSc for the data management of the NEO study. This work was supported by the participating Departments, the Division and Board of Directors of the Leiden University Medical Centre, the Leiden University Research Profile Area Vascular and Regenerative Medicine, the Netherlands Cardiovascular Research Initiative of the Dutch Heart Foundation (CVON2014-02 ENERGISE).

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.numecd.2019.03.010>.

References

- [1] Dale CE, Fatemifar G, Palmer TM, White J, Prieto-Merino D, Zabaneh D, et al. Causal associations of adiposity and body fat distribution with coronary heart disease, stroke subtypes, and type 2 diabetes mellitus: a mendelian randomization analysis. *Circulation* 2017;135(24):2373.
- [2] Recio-Rodriguez JI, Gomez-Marcos MA, Patino-Alonso MC, Agudo-Conde C, Rodriguez-Sanchez E, Garcia-Ortiz L, et al. Abdominal obesity vs general obesity for identifying arterial stiffness, sub-clinical atherosclerosis and wave reflection in healthy, diabetics and hypertensive. *BMC Cardiovasc Disord* 2012;12:3.
- [3] Lu Y, Hajifathalian K, Ezzati M, Woodward M, Rimm EB, Danaei G, et al. Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1.8 million participants. *Lancet* 2014;383(9921):970–83.
- [4] Lu Y, Hajifathalian K, Rimm EB, Ezzati M, Danaei G. Mediators of the effect of body mass index on coronary heart disease: decomposing direct and indirect effects. *Epidemiology* 2015;26(2):153–62.
- [5] Fontes JD, Yamamoto JF, Larson MG, Wang N, Dallmeier D, Rienstra M, et al. Clinical correlates of change in inflammatory biomarkers: the Framingham Heart Study. *Atherosclerosis* 2013;228(1):217–23.
- [6] Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. *Annu Rev Immunol* 2011;29:415–45.
- [7] Libby P, Hansson GK. Inflammation and immunity in diseases of the arterial tree: players and layers. *Circ Res* 2015;116(2):307–11.
- [8] Brooks GC, Blaha MJ, Blumenthal RS. Relation of C-reactive protein to abdominal adiposity. *Am J Cardiol* 2010;106(1):56–61.
- [9] Orvos JD, Shalaurava I, Wolak-Dinsmore J, Connelly MA, Mackey RH, Stein JH, et al. GlycA: a composite nuclear magnetic resonance biomarker of systemic inflammation. *Clin Chem* 2015;61(5):714–23.
- [10] Lawler PR, Akinkuolie AO, Chandler PD, Moorthy MV, Vandenberg MJ, Schaumberg DA, et al. Circulating N-linked glycoprotein acetyls and longitudinal mortality risk. *Circ Res* 2016;117(7):1106–15.
- [11] Sattar N, Murray HM, McConnachie A, Blauw GJ, Bollen ELEM, Buckley BM, et al. C-reactive protein and prediction of coronary heart disease and global vascular events in the prospective study of pravastatin in the elderly at risk (PROSPER). *Circulation* 2007;115(8):981–9.
- [12] Yasmin, McEniery CM, Wallace S, Mackenzie IS, Cockcroft JR, Wilkinson IB. C-reactive protein is associated with arterial

- stiffness in apparently healthy individuals. *Arterioscler Thromb Vasc Biol* 2004;24(5):969–74.
- [13] Elliott P, Chambers JC, Zhang WH, Clarke R, Hopewell JC, Peden JF, et al. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. *JAMA, J Am Med Assoc* 2009;302(1):37–48.
- [14] Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Silleesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. *N Engl J Med* 2008;359(18):1897–908.
- [15] Collaboration CRPCHDG, Wensley F, Gao P, Burgess S, Kaptoge S, Di Angelantonio E, et al. Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. *BMJ* 2011;342:d548.
- [16] Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. *N Engl J Med* 2017;377(12):1119–31.
- [17] Svenungsson E, Jensen-Urstad K, Heimbürger M, Silveira A, Hamsten A, de Faire U, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. *Circulation* 2001;104(16):1887–93.
- [18] Wensley F, Gao P, Burgess S, Kaptoge S, Di Angelantonio E, Shah T, et al. Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. *Br Med J* 2011;342.
- [19] Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ, et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. *Lancet* 2018;391(10118):319–28.
- [20] de Mutsert R, den Heijer M, Rabelink TJ, Smit JW, Romijn JA, Jukema JW, et al. The Netherlands Epidemiology of Obesity (NEO) study: study design and data collection. *Eur J Epidemiol* 2013;28(6):513–23.
- [21] Jette M, Sidney K, Blumchen G. Metabolic equivalents (METs) in exercise testing, exercise prescription, and evaluation of functional capacity. *Clin Cardiol* 1990;13(8):555–65.
- [22] van der Meer RW, Rijzewijk LJ, de Jong HW, Lamb HJ, Lubberink M, Romijn JA, et al. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. *Circulation* 2009;119(15):2069–77.
- [23] Christen T, Trompet S, Noordam R, Blauw LL, Gast KB, Rensen PCN, et al. Mendelian randomization analysis of cholesteryl ester transfer protein and subclinical atherosclerosis: a population-based study. *J Clin Lipidol* 2018 Jan-Feb;12(1):137–44.
- [24] Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. *Diabetes Care* 2004;27(6):1487–95.
- [25] Soininen P, Kangas AJ, Wurtz P, Suna T, Ala-Korpela M. Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. *Circ Cardiovasc Genet* 2015;8(1):192–206.
- [26] McConkey B, Davies P, Crockson RA, Crockson AP, Butler M, Constable TJ, et al. Effects of gold, dapsone, and prednisone on serum C-reactive protein and haptoglobin and the erythrocyte sedimentation rate in rheumatoid arthritis. *Ann Rheum Dis* 1979;38(2):141–4.
- [27] Tarp S, Bartels EM, Bliddal H, Furst DE, Boers M, Danneskiold-Samsøe B, et al. Effect of nonsteroidal antiinflammatory drugs on the C-reactive protein level in rheumatoid arthritis: a meta-analysis of randomized controlled trials. *Arthritis Rheum* 2012;64(11):3511–21.
- [28] Mv VWS. Hoeveel mensen hebben overgewicht?. Available at: <https://www.volksgezondheinzorginfo/onderwerp/overgewicht/cijfers-context/huidige-situatie>; 2013. Accessed December 20, 2016.
- [29] Korn EL, Graubard BI. Epidemiologic studies utilizing surveys: accounting for the sampling design. *Am J Public Health* 1991;81(9):1166–73.
- [30] Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. *J Personal Soc Psychol* 1986;51(6):1173–82.
- [31] le Cessie S, Debeij J, Rosendaal FR, Cannegieter SC, Vandembroucke JP. Quantification of bias in direct effects estimates due to different types of measurement error in the mediator. *Epidemiology* 2012;23(4):551–60.
- [32] Forouhi NG, Sattar N, McKeigue PM. Relation of C-reactive protein to body fat distribution and features of the metabolic syndrome in Europeans and South Asians. *Int J Obes* 2001;25(9):1327–31.
- [33] Samaras K, Botelho NK, Chisholm DJ, Lord RV. Subcutaneous and visceral adipose tissue gene expression of serum adipokines that predict type 2 diabetes. *Obesity* 2010;18(5):884–9.
- [34] Libby P. Inflammation in atherosclerosis. *Arterioscler Thromb Vasc* 2012;32(9):2045–51.
- [35] Gabay C, Kushner I. Mechanisms of disease: acute-phase proteins and other systemic responses to inflammation. *N Engl J Med* 1999;340(6):448–54.
- [36] VanderWeele TJ, Valeri L, Ogburn EL. The role of measurement error and misclassification in mediation analysis: mediation and measurement error. *Epidemiology* 2012;23(4):561–4.